 |
Stephen Flaim, Ph.D., F.A.C.C.
Deputy Director, Technology and Business Advisor, von Liebig Center
Jacobs School of Engineering, UCSD
Dr. Flaim received his graduate degree in Human Physiology and Pharmacology from the University of California at Davis in 1975. He assumed a faculty position in Medicine and Physiology at the Pennsylvania State University College of Medicine at Hershey, PA. His early research focused on the mechanisms controlling the peripheral circulation in congestive heart failure and also contributed to the understanding of the cellular effects of the class of compounds now known as calcium channel blockers. In 1982, he assumed a lead research position in charge of Antianginal Drug Discovery at McNeil Pharmaceutical, a division of Johnson & Johnson. He subsequently took the position of Associate Director of Cardiovascular Pharmacology at the Squibb Institute for Medical Research where he was responsible for the Ion Channel Regulation Drug Discovery Program. In 1990, Dr. Flaim joined Alliance Pharmaceutical Corporation in San Diego where he was Vice President of Biological Sciences. At Alliance, Dr. Flaim was responsible for the preclinical development of perfluorocarbon-based products for use as temporary oxygen carriers during high blood-loss surgeries, liquid ventilation therapy for respiratory distress, and contrast enhancement during echocardiography. Dr. Flaim then took the position of Vice President of Biological Research & Development with Trega Biosciences, Inc. in San Diego where he was responsible for the drug discovery & development programs in pain management, inflammation, metabolic diseases and obesity. In 1999, Dr. Flaim became Senior Vice President of Research & Development at Galileo Pharmaceuticals, Inc. in Santa Clara, CA. In this role, he had overall responsibility for pharmaceutical drug discovery and development programs in myocardial ischemia, stroke, and inflammation focusing on chronic neuroinflammatory diseases. He also was responsible for the preclinical and clinical development aspects of the company’s antiinflammatory bioactive neutraceutical programs. In 2003, Dr. Flaim established a private consulting firm supporting the biotechnology and pharmaceutical fields in the areas of preclinical and clinical research and development. Dr. Flaim is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a member of the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics, a Technology and Business advisor to the University of California School of Engineering William J. Von Liebig Center for Entrepreneurism and Technology Advancement, a member of the Board of Governors of the Tech Coast Angels, a member of the Executive Board of the San Diego Tech Coast Angels, an Entrepreneur-in-Residence with the CONNECT Springboard program and is also active in numerous regional and national scientific organizations.
